Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Boers

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
International Journal of Cancer|February 27, 2023
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trialsMelissa M de Meza, Willeke A M Blokx, Han J Bonenkamp, et al.
Fungal Systematics and Evolution|August 13, 2024
New and Interesting Fungi. 7C M Visagie, N Yilmaz, J D Allison, et al.
Cancers|October 23, 2021
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The NetherlandsJesper van Breeschoten, Alfonsus J M van den Eertwegh, Liesbeth C de Wreede, et al.
Cancers|August 10, 2024
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma PatientsDaan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, et al.
JAMA Network Open|August 14, 2024
Long-Term Survival in Patients With Advanced MelanomaOlivier J van Not, Alfons J M van den Eertwegh, Hilde Jalving, et al.
Melanoma Research|December 22, 2020
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastasesRawa K Ismail, Nienke O Sikkes, Michel W J M Wouters, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2020
Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based studyMichiel C T van Zeijl, Florine L Boer, Mariëtte I E van Poelgeest, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2023
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignanciesOlivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 27, 2023
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the NetherlandsMichiel C T van Zeijl, Jesper van Breeschoten, Liesbeth C de Wreede, et al.
BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
International Journal of Cancer|February 27, 2023
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trialsMelissa M de Meza, Willeke A M Blokx, Han J Bonenkamp, et al.
Fungal Systematics and Evolution|August 13, 2024
New and Interesting Fungi. 7C M Visagie, N Yilmaz, J D Allison, et al.
Cancers|October 23, 2021
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The NetherlandsJesper van Breeschoten, Alfonsus J M van den Eertwegh, Liesbeth C de Wreede, et al.
Cancers|August 10, 2024
Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma PatientsDaan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, et al.
JAMA Network Open|August 14, 2024
Long-Term Survival in Patients With Advanced MelanomaOlivier J van Not, Alfons J M van den Eertwegh, Hilde Jalving, et al.
Melanoma Research|December 22, 2020
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastasesRawa K Ismail, Nienke O Sikkes, Michel W J M Wouters, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2020
Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based studyMichiel C T van Zeijl, Florine L Boer, Mariëtte I E van Poelgeest, et al.
European Journal of Cancer (Oxford, England : 1990)|April 6, 2023
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignanciesOlivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 27, 2023
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the NetherlandsMichiel C T van Zeijl, Jesper van Breeschoten, Liesbeth C de Wreede, et al.
BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.
Pageof 13